Fitzsimons Innovation Community Welcomes Four New Board Members
Comprised of leaders representing the bioscience industry, University of Colorado, and the City of Aurora, the Board of Directors supports the vision of Fitzsimons Innovation Community.
-
-
26 Top BioPharma Startups & Companies (Colorado)
BioPharma companies have been making some huge strides over the last year with innovations driven by both established players and startups entering the scene. With an impressive 7.32% CAGR and a value of $325.17 billion in 2020 it is a huge industry ripe for growth.
-
CU School of Medicine Research Sparks Call-to-Action on Treating In-Hospital Stroke
CU SOM professor’s decade of research serves as backbone for improved care guidelines
-
Colorado Life Sciences Companies Raise a Record $2.4 Billion in 2021
Colorado’s life sciences ecosystem raised $2.4 billion in 2021, a new record for the fast-growing community that includes companies at all stages of commercialization and academic and research institutions. The 2021 fundraising total is double the $1.2 billion raised by the Colorado life sciences community in 2020. Sources of funding included headline-making IPOs, significant additional…
-
Fitzsimons Innovation Community First Annual Innovation Report: “United to Advance Health”
New report demonstrates Community momentum to meet speed-to-market urgency in biotech.
-
European Medicines Agency (EMA) Validates Atara Biotherapeutics’ Marketing Authorization Application
Atara Biotherapeutics announced that the Marketing Authorization Application (MAA) for tabelecleucel (tab-cel®) has been fully validated by the European Medicines Agency (EMA).
-
Pathways Bioscience Seeks to Optimize Aging
Pathways Bioscience’s technology improves healthspan and overcomes health and wellness problems associated with aging.
-
Two CU Cancer Center Members Recognized as World Experts in Pancreatic Neoplasms
Expertscape rankings recognize Richard Schulick, MD, and Marco Del Chiaro, MD, among the top 0.1% of scholars worldwide.
-
Taiga Initiates Phase 1/2 Clinical Study of TBX-2400 in Acute Myeloid Leukemia and Myelofibrosis in Croatia
TBX-2400 is expected to improve engraftment and reconstitution of immune system for patients receiving Hematopoietic Stem Cell Transplants.
-
Pharmaceutical Executive Podcast
Amie Krause, Senior Vice President and Chief People Officer, and Kristin Yarema, Chief Commercial Officer, of Atara Biotherapeutics, discuss women in leadership positions in pharma and the effects of a gender diverse company.
